Biologic Therapy for the Management of Eosinophilic Esophagitis in Children: The Evolving Treatment Paradigm

This activity includes patient counseling video vignettes.

Program Description

A deeper understanding of the pathophysiology of eosinophilic esophagitis (EoE), an immune-mediated condition of the esophagus causing inflammation, has led to the discovery of various targets that may be susceptible to biologic therapy. With the expanding treatment options for pediatric patients with EoE have come additional goals of therapy beyond symptomatic improvement. Targeted therapies in EoE aim for mucosal healing, fibrosis prevention, quality of life improvement, social activity restoration, feeding dysfunction correction, and prevention of nutritional deficiencies in children. As biologics continue to be developed and expand their indications in EoE, specialty pharmacists are becoming increasingly integral to patients, their caregivers, and the multidisciplinary care team. This session will focus on the significant quality of life burden of EoE and the role of approved biologic therapy. Patient case video vignettes will be integrated into this session to highlight the role of the specialty pharmacist in assisting caregivers and patients with therapy initiation and optimization.

Target audience: Specialty pharmacists

Type of activity: Application
Release date: July 24, 2024
Expiration date: July 24, 2025

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate the significant burden of eosinophilic esophagitis (EoE) in the pediatric population
• Explain safety and efficacy data for approved and emerging biologic therapy for the management of EoE
• Illustrate the role of the pharmacist in supporting the patient and caregiver journey in the management of EoE

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-225-H01-P. The activity is available for CE credit through July 24, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Erin P. Syverson, MD, has the following financial relationships with commercial interests to disclose:
Advisory Board: Sanofi

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Amanda M. Kibbons, PharmD

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose. 

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms